INTREXON CORPORATION (NYSE:XON) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
Attached as Exhibit 99.1 is a copy of a press release of Intrexon
Corporation, dated March1, 2017, reporting its financial results
for the quarter and year ended December31, 2016.
Such information, including the Exhibit attached hereto, shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, except
as shall be expressly set forth by specific reference in such
filing.
| Item7.01. | Regulation FD Disclosure. |
On March1, 2017, Intrexon Corporation provided slides to
accompany its earnings presentation. A copy of the slides is
furnished as Exhibit 99.2 hereto.
Such information, including the Exhibit attached hereto, shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, except
as shall be expressly set forth by specific reference in such
filing.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
99.1 |
Press release dated March1, 2017. | |
|
99.2 |
Slide presentation of Intrexon Corporation, dated March1, 2017. |
2
About INTREXON CORPORATION (NYSE:XON)
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform. INTREXON CORPORATION (NYSE:XON) Recent Trading Information
INTREXON CORPORATION (NYSE:XON) closed its last trading session down -0.46 at 21.80 with 1,540,761 shares trading hands.